Phathom Pharmaceuticals
PHAT
About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees: 427
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
37% more capital invested
Capital invested by funds: $401M [Q1] → $550M (+$149M) [Q2]
27% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $12.1M
16% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
9.73% less ownership
Funds ownership: 91.94% [Q1] → 82.2% (-9.73%) [Q2]
15% less funds holding
Funds holding: 137 [Q1] → 117 (-20) [Q2]
50% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 36
Financial journalist opinion
Based on 4 articles about PHAT published over the past 30 days
